CellCentric
@CellCentric
Followers
687
Following
1
Media
451
Statuses
643
Inobrodib (CCS1477): first-in-class p300/CBP small molecule inhibitor drug, to treat specific cancers.
Cambridge, UK
Joined November 2009
PRESS RELEASE: @DrEmmaSearle at #ASH24 shared latest positive inobrodib clinical data in treating multiple myeloma.
0
3
2
We will be sharing latest clinical data on Monday 5pm PT at #ASH24, San Diego. Inobrodib, our novel oral drug, new MoA, to treat multiple myeloma.
0
1
0
We will be at #ASH24, presenting latest Phase II data: New Drug in Multiple Myeloma, Dec 9th. Novel MoA, additive to, complementing existing treatments.
0
1
2
Delighted to have such a strong network of advisors supporting inobrodib’s drug development. See:
0
0
1
2 weeks to go…! We’ll be sharing latest clinical data at #ASH24, San Diego. New Drug for Multiple Myeloma. See:
0
1
1
RT @CellCentric: We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: h….
0
1
0
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See:
0
1
3
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
1
1
0
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
0
1
2
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
0
1
3
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
0
1
1
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
0
0
0
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See:
0
1
1
Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. Endpoints coverage:
0
1
2
Tomasz and Kris in Madrid for #EHA2024. CellCentric’s novel oral drug, inobrodib, in Phase II trials for multiple myeloma.
0
0
1
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post:
0
3
2
Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.
0
0
2
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
0
0
0
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
0
1
0
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
0
0
3